Ardelyx (ARDX)

• Market cap: $1.35B
• 1 day: -4.13%
• 5 days: -7.48%
• 1 month: 9.22%
• 3 months: -4.95%
• 6 months: 37.19%
• Year to date: 8.79%
• 1 year: 16.28%
• 5 years: -2.45%
• 10 years: -67.25%
• Sector: Healthcare
• Industry: Biotechnology

About: Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

Employees: 395